US FDA's Centralized Patient Affairs Office Aims For No Disruption
New office will develop agency-wide patient engagement policy and serve as entry point for patient groups new to FDA, but will not interfere with existing relationships between advocates and the drugs and biologics centers, FDA Commissioner Gottlieb says.
You may also be interested in...
The agency's principle deputy commissioner says it's creating a patient affairs staff, but will not undergo a reorganization.
Rachel Sherman says agency is creating patient affairs staff, but will not undergo reorganization to create an official office.
US FDA Commissioner intends to change agency's siloed structure and move reviewers into teams that will follow products pre- and post-market.